Revolution Medicines (RVMD) Cash from Investing Activities (2019 - 2026)

Revolution Medicines' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $172.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 1182.29% year-over-year to $172.6 million; the TTM figure through Mar 2026 stood at $306.6 million (up 195.11% YoY), while the FY2025 annual figure was $118.1 million, up 121.29% from the prior year.
• Cash from Investing Activities was $172.6 million for Q1 2026 at Revolution Medicines, up from $74.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $172.6 million in Q1 2026 to a low of -$392.9 million in Q4 2024.
• Historically, Cash from Investing Activities has averaged -$37.1 million across 5 years, with a median of $4.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities soared 1806.67% in 2022, then plunged 6305.36% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$7.1 million in 2022, then sank by 5254.76% to -$380.4 million in 2023, then dropped by 3.29% to -$392.9 million in 2024, then surged by 119.06% to $74.9 million in 2025, then jumped by 130.52% to $172.6 million in 2026.
• The last three Cash from Investing Activities figures came in at $172.6 million (Q1 2026), $74.9 million (Q4 2025), and $24.8 million (Q3 2025), per Business Quant data.